endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Dou­bling down on Sanofi's French roots, Paul Hud­son in­fus­es €50M in­to Jeito Cap­i­tal to boost home­grown biotechs

5 years ago
Financing

Chas­ing a 'mas­ter mod­u­la­tor' in the en­do­cannabi­noid sys­tem, biotech up­start promis­es to shake up neu­ropsy­chi­atric ...

5 years ago
Financing
Startups

Covid-19 roundup: Po­lit­i­cal pres­sures at FDA con­tin­ue post-elec­tion; Med­ica­go takes GSK ad­ju­vant in­to its first ...

5 years ago
Coronavirus

A can­cer vac­cine that might work? Mod­er­na posts 'promis­ing' ear­ly snap­shot for Mer­ck-part­nered pro­gram and raids ...

5 years ago
R&D

Cit­ing tox­i­c­i­ty con­cerns, Boehringer In­gel­heim drops short-lived IPF pact — keep­ing $1B+ in its pock­et

5 years ago
Deals

Covid-19 roundup: Sinopharm touts 'bet­ter than ex­pect­ed' PhI­II vac­cine da­ta; Af­ter Pfiz­er/BioN­Tech, Rus­sia claims ...

5 years ago
Coronavirus

As­traZeneca, Am­gen tout PhI­II win for 'break­through' asth­ma drug, check­ing a block­buster box that Dupix­ent did­n't

5 years ago
R&D

Covid-19 roundup: With ef­fi­ca­cy da­ta in hand, BioN­Tech talks pric­ing; Brazil halts Sino­vac tri­al fol­low­ing pa­tient ...

5 years ago
FDA+
Coronavirus

Sweep­ing doubts aside, Eli Lil­ly beats Re­gen­eron to emer­gency OK — clear­ing low dose an­ti­body for quick roll­out

5 years ago
FDA+
Coronavirus

Leg­end Biotech has a new chair­woman and per­ma­nent CEO. But where is Frank Zhang?

5 years ago
People
Cell/Gene Tx

GSK re­ports its long-act­ing HIV PrEP tops Gilead­'s Tru­va­da — again

5 years ago
R&D

News brief­ing: Cosen­tyx shows ear­ly pos­i­tive signs in pso­ri­at­ic arthri­tis; Pfiz­er's PhI­Ib for car­dio drug trig­gers ...

5 years ago
News Briefing

Bio­Marin gets its dwarfism drug in the FDA's door — but can they change reg­u­la­tors’ minds about a longer fol­low ...

5 years ago
FDA+

FDA scut­tles blue­bird's ac­cel­er­at­ed plans for sick­le cell gene ther­a­py, as high­er CMC bar forces 1-year de­lay

5 years ago
Outsourcing
Cell/Gene Tx

A year af­ter stun­ning Chi­na OK, Shang­hai Alzheimer's drug­mak­er set to en­roll first US pa­tient — and the stakes are ...

5 years ago
R&D
China

JW Ther­a­peu­tics hauls in $300M IPO just as liso-cel-in­spired CAR-T nears the fin­ish line in Chi­na

5 years ago
Financing
China

Covid-19 roundup: Russ­ian biotech seeks per­mis­sion to pro­duce remde­sivir gener­ic; Why did BAR­DA fund plas­ma com­pa­ny ...

5 years ago
Coronavirus

Roy­al­ty Phar­ma tops its record-set­ting $3.3B deal with CF Foun­da­tion, bet­ting $575M more on Ver­tex's drugs

5 years ago
Deals

Re­gen­eron slams the brakes on rare dis­ease tri­al fol­low­ing pa­tient deaths — cast­ing more doubt on a drug with mixed ...

5 years ago
R&D

News brief­ing: Ax­o­vant faces months of de­lay on lead Parkin­son's gene ther­a­py; Chi­nese CAR-T biotech nabs $100M

5 years ago
News Briefing

Covid-19 roundup: Flush with $486M con­tract, As­traZeneca signs Lon­za up to man­u­fac­ture an­ti­bod­ies; BioN­Tech's Ugur ...

5 years ago
Coronavirus

Bel­licum slash­es 79% of staffers af­ter ear­ly da­ta quash hope around next-gen CAR-T

5 years ago
People
Cell/Gene Tx

Q32 Bio grabs $60M to kick off hu­man stud­ies for next-gen com­ple­ment drugs — with some Covid-19 tweaks along the ...

5 years ago
Financing

Per­cep­tive re­cruits A-list in­vestors to back its in-house Chi­na start­up with a mam­moth $310M raise

5 years ago
Financing
China
First page Previous page 62636465666768 Next page Last page
A service from the Financial Times